1. Severe diarrhoea due to use of P2Y12 inhibitor ticagrelor: a rarely reported adverse event
- Author
-
Abdel-Naser Elzouki, Khalid Rashid, Muhammad Aamir Waheed, and Hafeez Ur Rehman
- Subjects
Diarrhea ,medicine.medical_specialty ,Gastrointestinal bleeding ,Acute coronary syndrome ,Ticagrelor ,medicine.medical_treatment ,Hemorrhage ,Case Report ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,P2Y12 ,Percutaneous Coronary Intervention ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Acute Coronary Syndrome ,Adverse effect ,Aged ,Aspirin ,business.industry ,Percutaneous coronary intervention ,General Medicine ,medicine.disease ,Conventional PCI ,Purinergic P2Y Receptor Antagonists ,Female ,business ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
Ticagrelor is a part of dual antiplatelet therapy (DAPT) which has proven benefits in patients with acute coronary syndrome especially in those undergoing percutaneous coronary intervention (PCI). However, like most other drugs, it can lead to undesired and adverse effects such as dyspnoea, easy bruising and gastrointestinal bleeding. We present a case of 70-year-old woman who developed diarrhoea following initiation of DAPT comprising of aspirin and ticagrelor following PCI. After excluding more common causes, it was attributed to ticagrelor administration and completely resolved after it was replaced with another oral antiplatelet agent. On follow-up, the patient reported complete resolution of symptoms.
- Published
- 2023